PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27253629-4	2016	The proportion of cells in G0/G1 phase was significantly higher among cells treated with 1 muM rapamycin for 3 days (D3-1R) than among control and serum-starved cells (p < 0.05).	Sirolimus	95-104	latexin	Homo sapiens	91-94	
26069529-6	2015	Sirolimus (10 muM) inhibited renal (22%, p = 0.002), hepatic (39%, p < 0.001), and cardiac (42%, p = 0.005) cellular respiration.	Sirolimus	0-9	latexin	Homo sapiens	14-17	
26104664-6	2015	RESULTS: Comparison of the acetylcholine-induced relaxation revealed a significant concentration-dependent decrease to 66 +- 7 % and 36 +- 7 % (mean +- SEM) after 20-h incubation with 1 and 10 muM rapamycin.	Sirolimus	197-206	latexin	Homo sapiens	193-196	
26104664-8	2015	Western blots after 20-h incubation with rapamycin (10 nM-1 muM) revealed a significant and concentration-dependent reduction of p (Ser 1177)-eNOS (down to 38 +- 8 %) in human mammary epithelial cells (Hmec)-1.	Sirolimus	41-50	latexin	Homo sapiens	60-63	
23479136-7	2013	Second-generation drugs induced more potent growth inhibition than rapamycin analogs at concentrations >0.03 muM in parental cells, SK-Sora, and 786-Suni cells.	Sirolimus	67-76	latexin	Homo sapiens	112-115	
26045804-6	2015	Sirolimus (10 muM) inhibited renal (22%, P=0.002), hepatic (39%, P<0.001), and cardiac (42%, P=0.005) cellular respiration.	Sirolimus	0-9	latexin	Homo sapiens	14-17	
25049998-4	2014	Rapamycin treatment of aged oocytes for 24 h (68 h in vitro maturation [IVM]; 44 h+10 muM rapamycin/24 h, 47.52+-5.68) or control oocytes (44 h IVM; 42.14+-4.40) significantly increased the development rate and total cell number compared with untreated aged oocytes (68 h IVM, 22.04+-5.68) (p<0.05).	Sirolimus	0-9	latexin	Homo sapiens	86-89	
23479136-4	2013	However, SK-Sora cells were more sensitive to rapamycin analogs (>=1 muM) than SK-HEP1 cells.	Sirolimus	46-55	latexin	Homo sapiens	72-75	
31564190-9	2019	Furthermore, DMEC (5, 10, and 20 muM) reduced the expression of phosphatidylinositol-3-kinase (PI3K), phosphorylated (p)-protein kinase B (Akt), and p-mammalian target of rapamycin (p-mTOR), which were further evidenced by pretreatment with IGF-1, a PI3K activator.	Sirolimus	171-180	latexin	Homo sapiens	33-36